The combination of molecular chemotherapy with radiation therapy has the potential to become a powerful approach for treatment of pancreatic cancer. We have developed an adenoviral vector (AdbCD-D314A) encoding a mutant bacterial cytosine deaminase (bCD) gene, which converts the prodrug 5-fluorocytosine (5-FC) into the active drug 5-fluorouracil. The aim of this study was to investigate AdbCD-D314A/5-FC-mediated cytotoxicity in vitro and therapeutic efficacy in vivo alone and in combination with radiation against human pancreatic cancer cells and xenografts. AdbCD-D314A/5-FC-mediated cytotoxicity alone and in combination with radiation was analyzed using crystal violet inclusion and clonogenic survival assays. CD enzyme activity was determined by measuring conversion of [ 3
Introduction
Pancreatic cancer is a common, highly lethal disease that is rising in incidence. Despite advances in the treatment of pancreatic cancer, the prognosis for locally advanced or metastatic disease remains very poor. Thus, the development of more effective alternative treatments will be critical to improve the survival of patients with these tumors (1 -3) . Among these approaches, molecular chemotherapy has received considerable attention (4) .
One of the most widely used molecular chemotherapy systems for cancer uses cytosine deaminase (CD) in combination with the antifungal agent 5-fluorocytosine (5-FC) that has been investigated intensely during the last decade. CD is a bacterial (bCD) or yeast enzyme that can convert 5-FC into the chemotherapy agent 5-fluorouracil (5-FU). 5-FU molecules are able to diffuse across the cell membrane into adjacent cells without passing through the gap junctions to produce a powerful bystander effect (5) . It has been shown that 5-FU is a strong radiosensitizer and the increased radiation sensitivity in cells exposed to 5-FU depends on G 1 -S-phase progression (6) .
Molecular chemotherapy using bCD or yeast CD has been studied for pancreatic cancer treatment in vitro and in animal tumor models (7 -9) . A major problem associated with this molecular chemotherapy approach is the low affinity displayed by the wild-type bCD (bCDwt) gene product toward 5-FC in comparison with cytosine. Recent studies have shown that substitution of an alanine (A) for the aspartic acid (D) at position 314 of bCDwt increased relative specificity of the mutant bCD-D314A enzyme to 5-FC in comparison with bCDwt and may be a superior gene for molecular chemotherapy (10, 11) . The utilization of bCD-D314A mutant for pancreatic cancer molecular chemotherapy should increase efficacy as well as decrease possible adverse effects.
The purpose of this study was to evaluate cytotoxicity in vitro and therapeutic efficacy in vivo of the combination of a nonreplicative adenovirus encoding bCD-D314A gene (AdbCD-D314A) and radiation against human pancreatic cancer. Animal model studies using human pancreatic tumor xenografts in nude mice examined the therapeutic efficacy of mutant bCD-D341A/5-FC therapy alone or in combination with radiation therapy. The results show that adenovirus-mediated bCD-D314A gene expression and 5-FC significantly enhanced cytotoxicity of pancreatic cancer cells in combination with radiation and increased efficacy against human pancreatic tumor xenografts in vivo compared with AdbCDwt/5-FC and radiation.
Materials and Methods
Recombinant Adenoviruses A replication-deficient AdbCDwt recombinant adenovirus vector encoding the gene for wild-type CD enzyme from Escherichia coli (bCD) under control of the human cytomegalovirus immediate-early promoter was constructed as described previously (12) . The replicationdeficient AdbCD-D314A vector encoding the mutant bCD-D314A gene driven by the cytomegalovirus promoter was developed, propagated, and titered as described previously (13) .
Cell Culture, Animals, and Chemicals Human pancreatic cancer cell lines S2O13 and S2VP10 (a kind gift from Dr. Anthony Hollingsworth, University of Nebraska), MIA PaCa-2 and BxPC-3 (American Type Culture Collection), and HEK293 human embryonic kidney cells (Microbix Biosystems) were cultured in DMEM/F-12 (Mediatech) containing 10% fetal bovine serum (Summit Biotechnology). Panc2.03 human pancreatic cancer cells (a kind gift from Dr. Elizabeth Jaffee, Johns Hopkins University) were cultured in RPMI 1640 (Mediatech) and 10% fetal bovine serum (Summit Biotechnology).
Female athymic nude mice were purchased from the Frederick Cancer Research Facility and housed under aseptic conditions in microisolator cages and experiments were carried out according to the Institutional Animal Care and Use Committee approved protocols.
5-FC and 5-FU were purchased from Sigma and SP Pharmaceuticals, respectively.
In vitro Cytotoxicity Assay To measure the cytotoxicity of 5-FU and 5-FC, pancreatic cancer cells were plated into 96-well tissue culture plates at 5 Â 10 3 per well and allowed to adhere overnight. The next day, serial dilutions of 5-FU or 5-FC were added directly to cells. Cells were incubated for 5 days, and relative cell density was determined using the crystal violet staining assay. Fractional cell survival at each drug concentration was calculated as the ratio of absorbance at 570 nm of cells incubated in the presence versus absence of drug, corrected for background absorbance of medium alone. Fractional cell survival data were plotted against drug concentration and IC 50 values were extrapolated by piecewise linear regression as the concentration of drug producing a 50% reduction in corrected absorbance.
For AdbCD-D314A/5-FC and AdbCDwt/5-FC cytotoxicity experiments, the target cells were plated into 96-well tissue culture plates at 5 Â 10 3 per well and allowed to adhere overnight. Twenty-four hours later, cells were infected with AdbCD-D314A or AdbCDwt at various multiplicities of infection. The next day, fresh medium supplemented with serial dilutions of 5-FC was added, and 5 days after prodrug treatment, cytotoxicity (IC 50 ) was determined using the crystal violet staining assay.
CD Conversion Assay Enzyme activity of bCDwt and bCD-D314A in pancreatic cancer cells was determined by measuring the conversion of [ 3 H]5-FC to [ 3 H]5-FU by TLC as described previously (13) . Clonogenic Survival Assay At 24 h after infection with 50 TCID 50 /cell of AdbCDwt or AdbCD-D314A, cells were trypsinized and diluted to the appropriate cell density into six-well culture plates and allowed to adhere overnight. 5-FC was added directly to cells the next day, and after 24 h incubation at 37jC, cells were either mock-irradiated or irradiated at 2 Gy using a 60 Co g-irradiator (Picker Unit) and were then returned to the incubator and cultured additionally for 15 days. Cells were then fixed with 70% ethanol and stained with 2% (w/v) crystal violet (Sigma-Aldrich). Colonies comprising at least 50 cells were counted. The plating efficiencies were calculated as the number of colonies divided by the number of test cells plated for each data point. Plating efficiencies were referenced back to the mock-irradiated control plating efficiency to determine the surviving fraction for each dose.
Flow Cytometry Annexin V staining and propidium iodide (PI) uptake were used for apoptosis evaluation. MIA PaCa-2 and Panc2.03 cells were infected with 50 TCID 50 /cell of AdbCDwt or AdbCD-D314A and allowed to incubate overnight. The next day, 5-FC or 5-FU was added to cell culture medium in final concentration of 50 or 15 Ag/mL, respectively. Twenty-four hours later, cells were either mock-irradiated or irradiated at 2 Gy. Cells were collected at 24 h after radiation and double stained with FITCconjugated Annexin V and PI. Annexin V and PI were added according to the manufacturer's recommendations (BioVision). Samples were immediately analyzed by FACScan. Annexin V and PI emissions were detected in the FL-1 (530/30 nm) and FL-2 (585/40 nm) channels, respectively. Analysis was done with CellQuest software (Becton Dickinson) on cells characterized by forward/side scatter variables. Annexin V-positive cells were considered apoptotic; cells taking only vital dye PI were considered necrotic. The percentages of apoptotic cells were calculated.
Western Blot MIA PaCa-2 and Panc2.03 cells were infected with 50 TCID 50 /cell of AdbCDwt or AdbCD-D314A. The next day, 5-FC or 5-FU was added to cell culture medium in final concentration of 50 or 15 Ag/mL, respectively. Twenty-four hours later, cells were either mock-irradiated or irradiated at 2 Gy. Cells were collected at 24 h after radiation, washed in TBS, and homogenized in lysis buffer (Sigma). Each sample was denatured for 5 min at 100jC in loading buffer. Equal amounts of protein (15 Ag) were loaded for each sample in all lanes and separated on SDS-PAGE followed by transfer to a polyvinylidene difluoride membrane. The membrane was incubated with anti-Bax, anti-Bcl 2 (NeoMarkers), or anti-Bcl XL (Santa Cruz Biotechnology) mouse monoclonal antibodies and then treated with the WesternBreeze Chemiluminescent Western Blot Immunodetection Kit (Invitrogen). The membrane was submerged in stripping buffer (Sigma) and incubated for 30 min at 50jC with occasional agitation, and expression of actin was detected. For immunodetection of actin, the rabbit polyclonal IgG (Santa Cruz Biotechnology) and polyclonal goat anti-rabbit Ig/ horseradish peroxidase (DAKO) and the Enhanced Chemiluminescence plus Western Blotting Detection System (Amersham Biosciences) were used.
CD Conversion inTumor Xenografts
For CD conversion assay, 7 Â 10 6 Panc2.03 pancreatic cancer cells were injected s.c. into athymic nude mice. When tumors reached 4 to 6 mm in diameter, they were injected with 1 Â 10 7 TCID 50 of AdbCD-D314A or AdbCDwt. Also, 1.6 Â 10 7 MIA PaCa-2 cells were resuspended 1:1 (v/v) in Matrigel (Becton Dickinson) and s.c. injected into athymic nude mice. Our initial in vivo studies showed that employing a reconstituted basement membrane, such as Matrigel, increased tumor take and growth of s.c. MIA PaCa-2 pancreatic tumor xenografts. Thus, Matrigel was used for establishment of MIA PaCa-2 tumor xenografts. MIA PaCa-2 tumors were injected with 5 Â 10 7 TCID 50 of AdbCD-D314A or AdbCDwt. Tumors were dissected at different times after adenovirus injection and crushed with a mortar and pestle in protease inhibitor buffer (Roche Diagnostics). Tumor tissues were frozen and thawed three times, and after centrifugation, the supernatant was assayed for protein concentration and subjected to CD conversion assay as described above. * Cells were incubated with serial dilutions of 5-FU, and IC 50 (Ag/mL) was determined at 5 days using the crystal violet staining assay. c Cells were infected with 50 TCID 50 /cell of AdbCD-D314A or AdbCDwt, and the next day, fresh medium supplemented with serial dilutions of 5-FC was added. 5-FC cytotoxicity was determined on day 5 after adenovirus infection by crystal violet staining assay.
AdbCDwt on days 0, 9, and 16. Three groups of animals (2, 4, and 5) received radiation therapy at 2 Gy on days 2, 10, and 17. All mice were treated i. 7 TCID 50 AdbCD-D314A or AdbCDwt on days 0, 7, and 14. Radiation treatment for three groups of animals (2, 4, and 5) was 2 Gy on days 2, 9, and 16. All mice were treated i.p. with 400 mg/kg 5-FC on days 1 to 5, 8 to 12, and 15 to 19. Tumor size was monitored twice a week using digital Vernier calipers. Tumor volumes were calculated as 0.5 Â length Â width 2 (mm 3 ).
Statistical Methods
All error terms are expressed as the SD of the mean. Significance levels for comparison of differences between groups in the in vitro experiments were analyzed by Student's t test. The differences were considered significant when P < 0.05. All reported P values are two-sided. In the animal model tumor therapy studies, the treatment groups were compared with respect to tumor size and percent of original tumor size over time. To test for significant differences in tumor volume doubling time between treatment groups, one-way ANOVA test was conducted. When the ANOVA indicated that a significant difference existed (P < 0.05), multiple comparison procedures were used to determine where the differences lay.
Results
Enzyme Activity of bCDwt and bCD-D314A In vitro To determine the CD enzyme activity, pancreatic cancer cells were infected with 25 TCID 50 /cell of AdbCD-D314A or AdbCDwt and the CD enzyme activity was determined by measuring the conversion of [ (Table 1) showed that the CD conversion activity was significantly (P < 0.001) elevated 336-, 406-, 160-, 917-, and 507-fold for MIA PaCa-2, BxPC-3, Panc2.03, S2VP10, and S2O13 cells, respectively, following infection with AdbCD-D314A, in comparison with the level of conversion activity in AdbCDwt-infected cells. The relative level of CD enzyme activity following infection with AdbCD-D314A was BxPC-3 > S2VP10 > MIA PaCa-2 > Panc2.03 > S2O13. Co g-irradiator. Data are presented as percentage of Annexin V-positive cells. Mean F SD of two independent experiments, each done in six replicates.
5-FU Sensitivity of Pancreatic Cancer Cell Lines

In vitro
To determine the sensitivity of pancreatic cancer cell lines to 5-FU, cells were treated with increasing concentrations of 5-FU, and the cytotoxicity of this drug was determined by measuring surviving cells using the crystal violet staining method. The susceptibility to cytotoxic effects of 5-FU was variable in different pancreatic cancer cell lines (Table 2) . Cell killing was proportional to the concentration of 5-FU used, and the range of concentration of 5-FU to produce 50% viable cells (IC 50 , 50% inhibitory concentration) was from 0.1 Ag/mL for BxPC-3 cells to 12.4 Ag/mL for the Panc2.03 cell line ( Table 2 The results of a long-term clonogenic survival assay (Table 3) show that the combination of molecular chemotherapy and ionizing radiation produced enhanced cell death in comparison with either treatment alone. The day after infection with 50 TCID 50 /cell of AdbCD-D341A or AdbCDwt, pancreatic cancer cells were treated with 5-FC at 4 Ag/mL; the next day, they were exposed to 2 Gy radiation and subjected to clonogenic survival assay (Table 3) . Radiation treatment alone caused a dose-dependent reduction in cell survival of uninfected cells (results not shown). AdbCD-D341A/5-FC treatment of pancreatic cancer cell lines produced a reduction in the number of colonies by 1.8-, 2.0-, 4.1-, 1.8-, and 2.2-fold for MIA PaCa-2, BxPC-3, Panc2.03, S2VP10, and S2O13 cells, respectively, compared (Table 3 ). There was a significantly greater reduction in the number of colonies following AdbCD-D341A/5-FC plus radiation treatment of MIA PaCa-2, BxPC-3, Panc2.03, S2VP10, and S2O13 cells (8.9-fold, P = 0.002; 21.3-fold, P = 0.0006; 21.1-fold, P = 0.0003; 5.4-fold, P = 0.004; and 18.5-fold, P = 0.0005, respectively) in comparison with AdbCD-D341A/5-FC alone treated cells. Combined treatment using radiation and AdbCD-D341A/5-FC enhanced cell killing, and the cytotoxic effect improved as the multiplicities of infection of AdbCD-D341A or concentration of 5-FC were increased (data not shown). There was greater cytotoxicity with AdbCD-D341A versus AdbCDwt in combination with 5-FC, radiation, or 5-FC plus radiation (Table 3) .
To investigate whether AdbCD-D341A/5-FC molecular therapy alone or in combination with radiation produce increased cell death through an apoptotic mechanism, MIA PaCa-2 and Panc2.03 cells were stained with both PI and FITC-labeled Annexin V (Table 4) . A significant increase in the percentage of apoptotic cells was observed after AdbCD-D341A/5-FC treatment in comparison with AdbCDwt/5-FC. Also, there was greater apoptosis in MIA PaCa-2 and Panc2.03 cells treated with AdbCD-D341A/5-FC in combination with radiation in comparison with AdbCD-D341A/5-FC alone. The results of sequential 5-FC dose-escalation studies showed a dose-dependent increased induction of apoptosis (data not shown).
Next, the expression of proapoptotic and antiapoptotic members of the Bcl 2 family of proteins was evaluated by Western blot analysis using antibodies against Bax, Bcl 2 , and Bcl XL proteins. Data shown in Fig. 1 show increased levels of Bax protein expression in MIA PaCa-2 and Panc2.03 after AdbCD-D341A/5-FC molecular therapy. Also, there was an increase in Bax expression following exposure to radiation and 5-FU. However, levels of expression of Bcl XL and Bcl 2 remained unchanged (Fig. 1) .
CD Conversion Activity of AdbCDwt and AdbCD-D314A in Human PancreaticTumor Xenografts
Taking into consideration the results of in vitro experiments, Panc2.03 and MIA PaCa-2 pancreatic cancer cell lines with different sensitivities to 5-FU were selected for an animal model study to investigate CD conversion activity after i.t. injection with AdbCDwt or AdbCD-D314A. The CD enzyme activity was determined by measuring the conversion of In vivo Therapy of Human Pancreatic Cancer Xenografts Using Molecular Chemotherapy Alone or in Combination with RadiationTreatment
Based on data not shown from an in vivo 5-FU doseescalation study, the maximum tolerated dose of 5-FU at 20 mg/kg, administered i.p. qdx5/wk for 3 weeks, was chosen to investigate the therapeutic effect of this drug alone versus in combination with radiation treatment. Panc2.03 cells (6 Â 10 6 ) were s.c. injected into athymic nude mice. In vivo tumor therapy was initiated on day 0, which corresponded to 11 days post-tumor cell injection. The baseline mean and SD for tumor volumes on day 0 was 109.8 F 8.6 mm 3 . The mean time to tumor doubling for PBS alone, 5-FU alone, PBS plus radiation, and 5-FU plus radiation groups were 34, 42, 56, and 67 days, respectively ( Fig. 2A ). There were no significant differences in tumor doubling times between groups that received 5-FU alone versus PBS plus radiation or PBS plus radiation versus 5-FU plus radiation (P > 0.05). However, the group treated with 5-FU plus radiation versus 5-FU alone showed significant differences in the time to tumor doubling (P = 0.03).
To compare antitumor effects of AdbCD-D314A-and AdbCDwt-mediated molecular chemotherapy on established solid tumors, 7 Â 10 6 Panc2.03 cells were s.c. injected into athymic nude mice. In vivo tumor therapy was initiated on day 0, which corresponded to 11 days posttumor cell injection. The baseline mean and SD for tumor volumes on day 0 was 118.8 F 13.7 mm (Fig. 2B ). There were no significant differences in tumor doubling times between groups that received 1 Â 10 7 TCID 50 per tumor of AdbCDwt/5-FC in comparison with PBS/5-FC or AdbCD-D314A/PBS (P > 0.05). Comparison of tumor doubling times of the AdbCD-D314A/5-FC treatment group versus the AdbCDwt/5-FC group showed a significant difference (P = 0.02).
We next determined whether a combination of molecular chemotherapy with radiation therapy increases tumor growth inhibition. Panc2.03 cells (7 Â 10 6 ) were injected s.c. into athymic nude mice. In vivo tumor therapy was started on day 0, which corresponded to 10 days posttumor cell injection. The baseline mean and SD for tumor volumes on day 0 was 86.0 F 9.1 mm (Fig. 2D ). There were no significant differences in tumor doubling times between groups treated with AdbCD-D314A/5-FC versus AdbCDwt/5-FC (P > 0.05). Comparison of mean time to tumor doubling of the group treated with AdbCD-D314A/5-FC plus radiation versus AdbCD-D314A/ 5-FC alone or AdbCDwt/5-FC plus radiation showed significant differences between the groups (P < 0.05).
Discussion
Chemotherapy based on 5-FU administration has been shown to slightly prolong survival of patients with advanced pancreatic cancer (14) . Earlier randomized trials showed a significant benefit of combined radiation therapy with 5-FU in comparison with radiation alone (15, 16) or with chemotherapy alone in local pancreatic carcinoma (17) . It has been shown that adenovirus-mediated CD therapy, when the vector was directly injected into the tumor sites followed by systemic delivery of 5-FC, resulted in inhibition of pancreatic cancer growth (7). However, results from several studies have shown a limited response to this molecular chemotherapy strategy (18, 19) .
In the present study, we developed an adenoviral vector encoding the mutant bCD-D314A gene and investigated the activity of bCD-D314A gene transfer in combination with 5-FC prodrug therapy for treatment of human pancreatic cancer cells in vitro and tumor xenografts in vivo. It was shown previously that the D314A mutation in bCDwt decreased efficiency for endogenous cytosine, which can compete with 5-FC prodrug for the active enzyme site. The increased affinity for 5-FC resulted in a 19-fold relative substrate preference for 5-FC in comparison with bCDwt (10, 11) . Thus, the rationale for using the mutant bCD-D314A gene in these experiments was that the bCD mutant D314A would more effectively convert 5-FC to 5-FU and increase the antitumor activity.
The results of AdbCD-D314A-and AdbCDwt-mediated molecular chemotherapy showed that AdbCD-D314A/ 5-FC treatment produced enhanced cytotoxicity of pancreatic cancer cells in comparison with AdbCDwt/5-FC, which correlated with significantly increased CD conversion activity in AdbCD-D314A-infected cells. Also, these data show that combination AdbCD-D314A-mediated molecular chemotherapy with radiation therapy resulted in increased killing of cancer cells. The induction of apoptosis and the role of proapoptotic and antiapoptotic proteins of the Bcl 2 protein family were examined in pancreatic cancer cells after molecular chemotherapy in combination with radiation. This study showed that pancreatic cancer cell toxicity induced by AdbCD-D314A/5-FC alone and in combination with radiation is dependent on the activation of apoptosis and associated with increased Bax expression. Thus, the apoptosis induced by conversion of 5-FC to 5-FU may be a primary mechanism in AdbCD-D314A/5-FC molecular chemotherapy of pancreatic cancer cells. These data agree with our and other investigators observations that induction of apoptosis is linked with CD/5-FC-mediated cytotoxicity (20, 21) .
Despite the promise of such therapy, the development of resistance to 5-FU could decrease the efficacy of CDmediated therapy. The mechanisms for the resistance to 5-FU treatment include rapid degradation of 5-FU to nontoxic derivatives through the action of dihydropyrimidine dehydrogenase (uracil reductase; refs. 22, 23) , different expression levels of enzymes involved in 5-FU phosphorylation (24) , amplification of the thymidylate synthase gene (25, 26) , or reduction in the synthesis of folylpolyglutamine (27) . 5-FU is converted into 5-FdUMP via a two-step process that is activated only when 5-FU is present at high intracellular concentrations. Thus, poor efficiency of conversion of 5-FU into its toxic metabolites plays an important role in resistance to 5-FU cancer therapy.
Differences in adenovirus infectivity of cancer cells, variations in levels of CD expression within infected tumor cells, and intrinsic differences in sensitivity to 5-FU and radiation may contribute to overall efficacy of molecular chemotherapy in combination with radiation therapy. The in vitro studies revealed that pancreatic cancer cell lines showed different levels of CD enzyme activity as well as sensitivity to 5-FU and radiation. These factors as well as multiple pathways that are involved in regulation of response to radiation and 5-FU-mediated cytotoxicity resulted in significant variability of effectiveness of the combination of AdbCD-D314A/5-FC and radiation for the various pancreatic cancer cell lines. The precise mechanisms underlying the interaction of radiation and 5-FU are not clear. However, there are several potential pathways by which 5-FU could increase radiation sensitivity at the cellular level. Although the disruption of either RNA or DNA synthesis can produce cytotoxicity, a substantial body of evidence suggests that radiosensitization is a result of thymidylate synthase inhibition (28, 29) . It was shown that 5-FU produces tumor cell killing particularly during S phase, when cells are relatively radioresistant (30) . Also, the combination of 5-FU and radiation sensitization probably results in cells that are progressing inappropriately through S phase due to misrepair of DNA damage imposed by radiation. This loss of the S-phase checkpoint in cancer cells may provide the molecular basis for selective killing of tumors compared with normal tissues (31, 32) .
Higher levels of CD conversion activity in Panc2.03 and MIA PaCa-2 tumor xenografts injected with AdbCD-D314A were associated with increased therapeutic efficacy of AdbCD-D341A/5-FC molecular chemotherapy in comparison with AdbCDwt/5-FC. The animal therapy studies showed that AdbCD-D341A/5-FC in combination with radiation significantly increased the frequency of regression of tumor and the persistence of tumor growth inhibition in comparison with AdbCD-D314A/5-FC alone and radiation therapy alone. However, pancreatic cancer molecular chemotherapy using mutant bCD in combination with radiation did not achieve complete regressions, which resulted in tumor regrowth. It is possible that the progression of tumor after treatment was due to the short duration of treatment used in this particular regimen as well as a low dose of adenovirus and/or 5-FC. Thus, additional experiments that are outside the scope of the present study are required to determine the optimum regimen of pancreatic cancer molecular chemotherapy in combination with radiation therapy.
There are several approaches to increase specificity and improve efficacy of pancreatic cancer molecular chemotherapy using mutant bCD. The rationale behind molecular chemotherapy with CD and 5-FC is that, after targeted expression of the enzyme into tumor cells, these cells will be rendered sensitive to the cytotoxic action of 5-FU and be more sensitive to radiation treatment. As molecular chemotherapy is essentially a tumor-targeted chemotherapy, the systemic toxicity commonly associated with, and a major limitation of, conventional chemotherapy using 5-FU is avoided. Specifically targeted expression of CD should decrease systemic toxicity and result in a high drug concentration in the tumor mass and an improved therapeutic index compared with systemic 5-FU administration. Thus, tumor-targeted molecular chemotherapy is an attractive approach for locally advanced pancreatic cancer therapy because local gene delivery is feasible. The utilization of replication-competent adenoviruses with selective oncolytic activity may increase therapeutic efficacy of molecular chemotherapy of pancreatic cancer. Oncolytic virotherapy in combination with molecular chemotherapy may produce cytotoxicity by several mechanisms including tumor-targeted CD expression, direct lysis of infected tumor cells as result of viral replication, and induction of inflammatory cytokine expression and T-cell-mediated immune response (33 -35) . Recently, it was shown that the combination of conditionally replicating adenovirus with 5-FU in subtoxic concentrations can improve virotherapy due to increased adenoviral uptake (36) and blocking cells in the S or G 2 phases of the cell cycle (37) . In the last decade, several conditionally replicating vectors encoding the CD gene were tested in various preclinical tumor model studies alone and in combination with radiation therapy, including glioma (38) , melanoma (39, 40) , prostate cancer (41, 42) , and pancreatic cancer (43) . These studies showed that using conditionally replicating vectors encoding CD in combination with radiation enhanced therapeutic efficacy of molecular chmoetherapy.
In summary, a novel mutant bCD-D314A for suicide gene/5-FC prodrug molecular chemotherapy in combination with radiation therapy produced markedly increased cytotoxicity in human pancreatic cancer cells in vitro and tumor xenografts in vivo. 
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